Picoplatin Value Proposition Multiple development paths to market Patients previously treated with a platinum agent Platinums not approved or accepted as standard of care First-line head-to-head vs. another platinum Poised for registration strategies in multiple indications Leveraging clinical insights from ~1,100 patients data Targeting variety of tumor indications and settings Lung Cancers (Small Cell Lung and Non Small Cell Lung Cancers) Colorectal Cancer Prostate Cancer Ovarian Cancer Preferred platinum agent in combination with partner's product pipeline Potential synergy with partner's products Portfolio opportunity for multiple indications to mitigate development risks Fast-to-market potential with existing data Address near term pipeline gap Near term revenue potential